No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 8
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Sionna Therapeutics, Inc. (SION) stock was $4.75 as of Oct 6, 2026, 4:00 PM EDT, down 2.06% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -83.7%
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.64
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.66
vs Estimate
$-0.65
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SION | $214.46M | $4.75 | -2.06% | -83.70% | N/A | N/A | N/A |
| 2NAGE | $214.24M | $2.69 | +0.37% | -61.15% | -15.72% | -1.06% | vs SION |
| 3NNNN | $215.07M | $4.90 | +1.45% | -84.84% | N/A | N/A | vs SION |
| 4PRLD | $216.91M | $3.81 | +1.06% | +155.31% | -33.98% | N/A | vs SION |
| 5LYEL | $210.98M | $8.61 | -5.07% | -48.74% | -48.18% | N/A | vs SION |
| 6KROS | $218.30M | $11.01 | -4.43% | -27.62% | -21.98% | N/A | vs SION |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$21.00
+342.1% upside
Low
$5.00
Current
$4.75
High
$63.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.71 | $-0.64 | $-0.54 | 5 |
| Quarter ending Dec 2026 | $-0.71 | $-0.56 | $-0.42 | 5 |
| Quarter ending Mar 2027 | $-0.51 | $-0.51 | $-0.51 | 3 |
| Quarter ending Jun 2027 | $-0.50 | $-0.50 | $-0.50 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.68 | $-2.48 | $-2.22 | 8 |
| FY 2027 | $-3.33 | $-2.29 | $-1.64 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $2.59M | $2.73M | $2.86M | 10 |
